IP2-ATLANTA
Trial Details
- Trial statusRecruiting
- Study email contactatlanta@imperial.ac.uk
- Chief InvestigatorProfessor Hashim U. Ahmed
- Project managerMrs Johanna Sukumar
- SponsorImperial College London
- ISRCTN number58401737
- PhaseII
- View clinicaltrials.gov website
- View dedicated study website
An unblinded randomised controlled trial to test a new way to treat advanced disease, targeting the initial tumour inside the prostate to slow the growth of other tumours around the body.
Design and Objective
Comparing standard treatment (Control Arm) to standard treatment with minimally invasive ablative therapy- heat/freeze (Arm 1) or radical therapy- radiotherapy/prostatectomy (Arm 2). Some men in arm 1 and 2 will also get treatment to metastases. Aim is to find differences between 3 arms in terms of treating cancer, side effects and quality of life.
Key inclusion criteria
Men who are willing to undergo local therapy and mets-directed therapy for metastatic prostate cancer in addition to standard of care systemic treatment.